Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG)
Phase 1 Trial of Marizomib Alone and in Combination With Panobinostat for Children With Diffuse Intrinsic Pontine Glioma
Sponsor: Celgene
Terminated
Withdrawal of support from BMS
Listed as NCT04341311, this PHASE1 trial focuses on Diffuse Glioma and Diffuse Intrinsic Pontine Glioma and remains terminated or withdrawn. Sponsored by Celgene, it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Dana-Farber Cancer Institute
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .